TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07888699: A Multicenter, Randomized, Double-Blind, Placebo-Controlled PhaseⅡ Study to Evaluate the Efficacy and Safety of WST03 Capsule Combined With Metronidazole for Bacterial Vaginosis

Sponsor: SPH Sine Pharmaceutical Laboratories Co., Ltd. · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 150 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$4,968,600

Rescue Site Savings

+$3,292,800

Unlock Full NCT07888699 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07888699 Rescue Dossier →